Instituto Grifols S.A.
PolandAll drugs from this manufacturer
-
It is used to replenish and maintain circulating blood volume in situations where a deficiency has been identified and the use of a plasma substitute is indicated.
Dosage form: solution for infusion
Active substance Dosage human albumin solution 200 g/1 l ATC: B05AA01
-
The medicinal product is used to replenish and maintain circulating blood volume in situations where a deficiency has been identified and the use of a plasma substitute is indicated.
Dosage form: solution for infusion
Active substance Dosage human albumin solution 50 g/1 l ATC: B05AA01
-
This is an anticoagulant used in the treatment of congenital antithrombin deficiency and in the prevention of deep vein thrombosis in the lower limbs and other blood vessels. It is also used in cases of acquired antithrombin deficiency, during surgical procedures, and in the perinatal period.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human antithrombin iii 500 j.m. ATC: B01AB02
-
It is an anticoagulant used in the treatment of congenital antithrombin deficiency and in the prevention of blood clots in the veins of the lower limbs and other blood vessels. It is also used in cases of acquired antithrombin deficiency, during surgical procedures, and in the perinatal period.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human antithrombin iii 1000 j.m. ATC: B01AB02
-
The medicinal product is used for the prevention and control of bleeding in patients with haemophilia A (congenital deficiency of coagulation factor VIII) and in patients with von Willebrand disease (VWD) when desmopressin treatment is ineffective or contraindicated. It may also be used in the treatment of acquired deficiency of human coagulation factor VIII.
Dosage form: powder and solvent for solution for injection and infusion
Active substance Dosage human blood coagulation factor viii 500 j.m. human von willebrand factor 600 j.m. ATC: B02BD06
-
The medicine is used for the prevention and control of bleeding in patients with hemophilia A (factor VIII deficiency) and in patients with von Willebrand disease (when desmopressin treatment is ineffective or contraindicated). It may also be used in the treatment of acquired factor VIII deficiency.
Dosage form: powder and solvent for solution for injection and infusion
Active substance Dosage human von willebrand factor 300 j.m. human blood coagulation factor viii 250 j.m. ATC: B02BD06
-
The medicinal product is used for the prevention and control of bleeding in patients with haemophilia A (deficiency of factor VIII) and in patients with von Willebrand disease (when desmopressin treatment is ineffective or contraindicated). It may also be used in the treatment of acquired factor VIII deficiency.
Dosage form: powder and solvent for solution for injection and infusion
Active substance Dosage human blood coagulation factor viii 1000 j.m. human von willebrand factor 1200 j.m. ATC: B02BD06
-
The medicinal product is used in adults, children, and adolescents for the treatment of antibody deficiencies (both congenital and acquired), prophylaxis of measles in susceptible individuals, and in the treatment of certain autoimmune diseases, such as immune thrombocytopenia, Guillain-Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and severe exacerbations of myasthenia gravis.
Dosage form: solution for infusion
Active substance Dosage human normal immunoglobulin 100 mg/ml ATC: J06BA02
-
The medicinal product is used to replenish and maintain circulating blood volume in situations where it is too low and plasma substitution is indicated.
Dosage form: solution for infusion
Active substance Dosage human albumin 200 g ATC: B05AA01
-
The medicinal product is used to prevent tetanus in individuals with fresh wounds that may be contaminated (especially if they have not been vaccinated in the last 10 years or if their vaccination history is unknown) and for the treatment of tetanus.
Dosage form: solution for injection
Active substance Dosage protein 160 mg ATC: J06BB02
-
It is used to prevent tetanus in individuals with fresh wounds that may be contaminated (especially if they have not been vaccinated within the last 10 years) and for the treatment of tetanus.
Dosage form: solution for injection
ATC: J06BB02
-
The medicine is used for long-term supportive treatment in individuals with alpha-1 antitrypsin deficiency. It aims to restore balance in the lungs and prevent further progression of pulmonary emphysema.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human alpha-1-proteinase inhibitor 4000 mg ATC: B02AB02
-
It is used for long-term adjunctive treatment in individuals with alpha-1-proteinase inhibitor deficiency. It aims to restore balance in the lungs and prevent further progression of pulmonary emphysema.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human alpha-1-proteinase inhibitor 5000 mg ATC: B02AB02
-
The medicine is used in adults, children, and adolescents with immunodeficiency to increase the concentration of antibodies (immunoglobulins) in the blood. It is intended for individuals with primary immunodeficiency, patients with hypogammaglobulinemia (e.g., in the course of chronic lymphocytic leukemia or multiple myeloma), and individuals following stem cell transplantation.
Dosage form: solution for injection, subcutaneous
Active substance Dosage normal human immunoglobulin (scig) 18 to 22 % ATC: J06BA01